Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 1
1996 2
1997 3
2014 3
2015 3
2016 5
2017 1
2018 6
2020 11
2021 20
2022 8
2023 4
2024 8
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

71 results

Results by year

Filters applied: . Clear all
Page 1
Cancer therapy with antibodies.
Paul S, Konig MF, Pardoll DM, Bettegowda C, Papadopoulos N, Wright KM, Gabelli SB, Ho M, van Elsas A, Zhou S. Paul S, et al. Among authors: konig mf. Nat Rev Cancer. 2024 Jun;24(6):399-426. doi: 10.1038/s41568-024-00690-x. Epub 2024 May 13. Nat Rev Cancer. 2024. PMID: 38740967 Free PMC article. Review.
Targeting public neoantigens for cancer immunotherapy.
Pearlman AH, Hwang MS, Konig MF, Hsiue EH, Douglass J, DiNapoli SR, Mog BJ, Bettegowda C, Pardoll DM, Gabelli SB, Papadopoulos N, Kinzler KW, Vogelstein B, Zhou S. Pearlman AH, et al. Among authors: konig mf. Nat Cancer. 2021 May;2(5):487-497. doi: 10.1038/s43018-021-00210-y. Epub 2021 May 17. Nat Cancer. 2021. PMID: 34676374 Free PMC article. Review.
Targeting a neoantigen derived from a common TP53 mutation.
Hsiue EH, Wright KM, Douglass J, Hwang MS, Mog BJ, Pearlman AH, Paul S, DiNapoli SR, Konig MF, Wang Q, Schaefer A, Miller MS, Skora AD, Azurmendi PA, Murphy MB, Liu Q, Watson E, Li Y, Pardoll DM, Bettegowda C, Papadopoulos N, Kinzler KW, Vogelstein B, Gabelli SB, Zhou S. Hsiue EH, et al. Among authors: konig mf. Science. 2021 Mar 5;371(6533):eabc8697. doi: 10.1126/science.abc8697. Epub 2021 Mar 1. Science. 2021. PMID: 33649166 Free PMC article.
Bispecific antibodies targeting mutant RAS neoantigens.
Douglass J, Hsiue EH, Mog BJ, Hwang MS, DiNapoli SR, Pearlman AH, Miller MS, Wright KM, Azurmendi PA, Wang Q, Paul S, Schaefer A, Skora AD, Molin MD, Konig MF, Liu Q, Watson E, Li Y, Murphy MB, Pardoll DM, Bettegowda C, Papadopoulos N, Gabelli SB, Kinzler KW, Vogelstein B, Zhou S. Douglass J, et al. Among authors: konig mf. Sci Immunol. 2021 Mar 1;6(57):eabd5515. doi: 10.1126/sciimmunol.abd5515. Sci Immunol. 2021. PMID: 33649101 Free PMC article.
TRBC1-targeting antibody-drug conjugates for the treatment of T cell cancers.
Nichakawade TD, Ge J, Mog BJ, Lee BS, Pearlman AH, Hwang MS, DiNapoli SR, Wyhs N, Marcou N, Glavaris S, Konig MF, Gabelli SB, Watson E, Sterling C, Wagner-Johnston N, Rozati S, Swinnen L, Fuchs E, Pardoll DM, Gabrielson K, Papadopoulos N, Bettegowda C, Kinzler KW, Zhou S, Sur S, Vogelstein B, Paul S. Nichakawade TD, et al. Among authors: konig mf. Nature. 2024 Apr;628(8007):416-423. doi: 10.1038/s41586-024-07233-2. Epub 2024 Mar 27. Nature. 2024. PMID: 38538786 Free PMC article.
Inside and Out.
Konig MF, Sathiyakumar V, Phan CM, Schulman SP, Gelber AC. Konig MF, et al. N Engl J Med. 2021 May 6;384(18):1753-1760. doi: 10.1056/NEJMcps2034360. N Engl J Med. 2021. PMID: 33951365 Free PMC article. No abstract available.
TCR β chain-directed bispecific antibodies for the treatment of T cell cancers.
Paul S, Pearlman AH, Douglass J, Mog BJ, Hsiue EH, Hwang MS, DiNapoli SR, Konig MF, Brown PA, Wright KM, Sur S, Gabelli SB, Li Y, Ghiaur G, Pardoll DM, Papadopoulos N, Bettegowda C, Kinzler KW, Zhou S, Vogelstein B. Paul S, et al. Among authors: konig mf. Sci Transl Med. 2021 Mar 10;13(584):eabd3595. doi: 10.1126/scitranslmed.abd3595. Epub 2021 Mar 1. Sci Transl Med. 2021. PMID: 33649188 Free PMC article.
Preclinical studies show that Co-STARs combine the advantages of chimeric antigen and T cell receptors for the treatment of tumors with low antigen densities.
Mog BJ, Marcou N, DiNapoli SR, Pearlman AH, Nichakawade TD, Hwang MS, Douglass J, Hsiue EH, Glavaris S, Wright KM, Konig MF, Paul S, Wyhs N, Ge J, Miller MS, Azurmendi P, Watson E, Pardoll DM, Gabelli SB, Bettegowda C, Papadopoulos N, Kinzler KW, Vogelstein B, Zhou S. Mog BJ, et al. Among authors: konig mf. Sci Transl Med. 2024 Jul 10;16(755):eadg7123. doi: 10.1126/scitranslmed.adg7123. Epub 2024 Jul 10. Sci Transl Med. 2024. PMID: 38985855
71 results